Oncology Clinical Trials in Westwood, KS

As of June 2026, 84 paid clinical trials are recruiting for Oncology in Westwood, Kansas. Oncology trials evaluate immunotherapies, targeted therapies, antibody-drug conjugates, and combination regimens across solid tumors and blood cancers — from early-phase first-in-human studies to phase 3 registration trials. Compensation typically covers time, travel, and study visits, and many studies also include study-related medical care at no cost.

Recruiting trial data synced daily from ClinicalTrials.gov. Last sync: June 12, 2026.

Filter results

Filter results

State

City

Facility

Phase

Study type

Intervention

Recruitment status

Condition

Sex

Age

Healthy volunteers only

84 clinical trials for Oncology

·Clear filters·↓ Download CSV

Study of AZD0754 in Participants With Metastatic Prostate Cancer

for Metastatic Prostate Cancer

13 locations incl. Duarte

Sponsor: AstraZeneca

Sex: Male·Age: 18 - 130

Code: NCT06267729·Phase 1, Phase 2·Recruiting

Apply to this trial

Cognitive Training for Cancer Related Cognitive Impairment in Breast Cancer Survivors

for Breast Cancer

673 locations incl. Anchorage

Sponsor: NRG Oncology

Sex: All·Age: 18 - 100

Code: NCT05896189·Recruiting

Apply to this trial

Cost Communication and Financial Navigation in Cancer Patients (COSTCOM)

for Malignant Solid Neoplasm

384 locations incl. Anchorage

Sponsor: ECOG-ACRIN Cancer Research Group

Sex: All·Age: All ages·Accepts healthy volunteers

Code: NCT06295367·Recruiting

Apply to this trial

A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer

for Carcinoma, Non-Small-Cell Lung

Drug: LY3537982

91 locations incl. Huntsville

Sponsor: Eli Lilly and Company

Sex: All·Age: 18+

Code: NCT06119581·Phase 3·Recruiting

Apply to this trial

Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With High Risk Prostate Cancer

for Prostate Adenocarcinoma

388 locations incl. Birmingham

Sponsor: NRG Oncology

Sex: Male·Age: 18+

Code: NCT05946213·Phase 3·Recruiting

Apply to this trial

A Long-term Follow-up Study of Subjects Who Received CRISPR CAR T Cellular Therapies

for Hematologic Malignancy

17 locations incl. Duarte

Sponsor: CRISPR Therapeutics AG

Sex: All·Age: 18+

Code: NCT06208878·Enrolling By Invitation

[177Lu]Lu-NeoB in Combination With Ribociclib and Fulvestrant in Participants With ER+, HER2- and GRPR+ Advanced Breast Cancer

for Breast Cancer

Drug: Ribociclib

6 locations incl. Los Angeles

Sponsor: Novartis Pharmaceuticals

Sex: All·Age: 18 - 100

Code: NCT05870579·Phase 1·Recruiting

Apply to this trial

Testing the Addition of an Anti-Cancer Drug, ZEN003694, to the Usual Chemotherapy Treatment (Capecitabine) for Metastatic or Unresectable Cancers

for Metastatic Colorectal Carcinoma

22 locations incl. Irvine

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: 18+

Code: NCT05803382·Phase 1·Recruiting

Apply to this trial

Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients

for Non-Small Cell Lung Cancer

Drug: Ivonescimab

76 locations incl. Phoenix

Sponsor: Summit Therapeutics

Sex: All·Age: 18+

Code: NCT05899608·Phase 3·Recruiting

Apply to this trial

Testing Continuous Versus Intermittent Treatment With the Study Drug Zanubrutinib for Older Patients With Previously Untreated Mantle Cell Lymphoma

for Mantle Cell Lymphoma

237 locations incl. Little Rock

Sponsor: Alliance for Clinical Trials in Oncology

Sex: All·Age: 60+

Code: NCT05976763·Phase 3·Recruiting

Apply to this trial

Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25

for Breast Cancer

1208 locations incl. Birmingham

Sponsor: NRG Oncology

Sex: Female·Age: 18 - 60

Code: NCT05879926·Phase 3·Recruiting

Apply to this trial

Evaluating the Impact of Social and Genetic Factors on Outcomes in Adolescent and Young Adult Cancer Survivors

for Hodgkin Lymphoma

428 locations incl. Anchorage

Sponsor: ECOG-ACRIN Cancer Research Group

Sex: All·Age: 18+

Code: NCT06002828·Recruiting

Apply to this trial

Testing the Combination of the Anti-Cancer Drugs Temozolomide and M1774 to Evaluate Their Safety and Effectiveness

for Advanced Malignant Solid Neoplasm

23 locations incl. Irvine

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: 18+

Code: NCT05691491·Phase 1, Phase 2·Recruiting

Apply to this trial

A Study to Compare Iberdomide Maintenance Versus Lenalidomide Maintenance Therapy Following Autologous Stem Cell Transplant in Participants With Newly Diagnosed Multiple Myeloma

for Multiple Myeloma

Drug: Iberdomide

44 locations incl. Aurora

Sponsor: Bristol-Myers Squibb

Sex: All·Age: 18+

Code: NCT05827016·Phase 3·Recruiting

Apply to this trial

Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma

for Diffuse Large B-Cell Lymphoma

87 locations incl. Tucson

Sponsor: SWOG Cancer Research Network

Sex: All·Age: 18+

Code: NCT05633615·Phase 2·Recruiting

Apply to this trial

Comparing Cooling and/or Compression Approaches of Limbs for Prevention of Chemotherapy-Induced Peripheral Neuropathy

for Malignant Solid Neoplasm

36 locations incl. Birmingham

Sponsor: SWOG Cancer Research Network

Sex: All·Age: 18+

Code: NCT05642611·Phase 3·Recruiting

Apply to this trial

SynKIR-110 for Mesothelin Expressing Ovarian Cancer, Cholangiocarcinoma or Mesothelioma

for Ovarian Cancer

5 locations incl. Tampa

Sponsor: Verismo Therapeutics

Sex: All·Age: 18+

Code: NCT05568680·Phase 1·Recruiting

Apply to this trial

A Safety and Efficacy Study Evaluating CTX112 in Subjects With Relapsed or Refractory B-Cell Malignancies

for B-cell Lymphoma

4 locations incl. Westwood

Sponsor: CRISPR Therapeutics AG

Sex: All·Age: 18+

Code: NCT05643742·Phase 1, Phase 2·Recruiting

Apply to this trial

Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)

for High Grade Epithelial Ovarian Cancer

37 locations incl. Phoenix

Sponsor: Genmab

Sex: All·Age: 18+

Code: NCT05579366·Phase 1, Phase 2·Recruiting

Apply to this trial

Testing the Combination of the Anti-cancer Drugs ZEN003694 (ZEN-3694) and Talazoparib in Patients With Advanced Solid Tumors, The ComBET Trial

for Advanced Malignant Solid Neoplasm

36 locations incl. Duarte

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: 18+

Code: NCT05327010·Phase 2·Recruiting

Apply to this trial

A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer

for Carcinoma, Non-small-Cell Lung

Drug: Amivantamab

26 locations incl. La Jolla

Sponsor: Janssen Research & Development, LLC

Sex: All·Age: 18+

Code: NCT05498428·Phase 2·Recruiting

Apply to this trial

A Study to Investigate the Efficacy and Safety of an Infusion of IOV-4001 in Adult Participants With Unresectable or Metastatic Melanoma or Stage III or IV Non-small-cell Lung Cancer

for Unresectable Melanoma

11 locations incl. Los Angeles

Sponsor: Iovance Biotherapeutics, Inc.

Sex: All·Age: 18 - 70

Code: NCT05361174·Phase 1, Phase 2·Recruiting

Apply to this trial

A Study of ASP3082 in Adults With Advanced Solid Tumors

for Solid Tumor

23 locations incl. Duarte

Sponsor: Astellas Pharma Inc

Sex: All·Age: 18+

Code: NCT05382559·Phase 1·Recruiting

Apply to this trial

A Study of ASP2138 Given by Itself or Given With Other Cancer Treatments in Adults With Stomach Cancer, Gastroesophageal Junction Cancer, or Pancreatic Cancer

for Gastric Adenocarcinoma

13 locations incl. Orange

Sponsor: Astellas Pharma Global Development, Inc.

Sex: All·Age: 18+

Code: NCT05365581·Phase 1·Recruiting

Apply to this trial

GPC3-Targeted T-Cell Therapy (ECT204) in Adults With Advanced HCC

for Hepatocellular Carcinoma

7 locations incl. Duarte

Sponsor: Eureka Therapeutics Inc.

Sex: All·Age: 18+

Code: NCT04864054·Phase 1, Phase 2·Recruiting

Apply to this trial

A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel

for Multiple Myeloma

28 locations incl. Phoenix

Sponsor: Janssen Research & Development, LLC

Sex: All·Age: 18+

Code: NCT05201781·Phase 4·Recruiting

Apply to this trial

A Study of Targeted Agents for Patients With Recurrent or Persistent Endometrial Cancer

for Endometrial Cancer

21 locations incl. Duarte

Sponsor: Alliance Foundation Trials, LLC.

Sex: Female·Age: 18+

Code: NCT04486352·Phase 1, Phase 2·Recruiting

Apply to this trial

Immune Checkpoint Inhibitor Toxicity Risk Prediction in Solid Tumors

for Malignant Solid Neoplasm

843 locations incl. Anchorage

Sponsor: SWOG Cancer Research Network

Sex: All·Age: 18+

Code: NCT04871542·Recruiting

Apply to this trial

Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study

for Chronic Lymphocytic Leukemia

621 locations incl. Birmingham

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: 18+

Code: NCT04269902·Phase 3·Recruiting

Apply to this trial

A Study to Compare Two Surgical Procedures in Individuals With BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer

for Ovarian Carcinoma

539 locations incl. Birmingham

Sponsor: NRG Oncology

Sex: Female·Age: 35 - 50

Code: NCT04251052·Recruiting

Apply to this trial

A Safety Study of SEA-CD70 in Patients With Myeloid Malignancies

for Myelodysplastic Syndrome

49 locations incl. Birmingham

Sponsor: Seagen, a wholly owned subsidiary of Pfizer

Sex: All·Age: 18+

Code: NCT04227847·Phase 1·Recruiting

Apply to this trial

Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])

for Lung Non-Small Cell Carcinoma

1150 locations incl. Anchorage

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: 18+

Code: NCT04267848·Phase 3·Recruiting

Apply to this trial

A Study of Sigvotatug Vedotin in Advanced Solid Tumors

for Carcinoma, Non-Small Cell Lung

Drug: sigvotatug vedotin

105 locations incl. Anchorage

Sponsor: Seagen, a wholly owned subsidiary of Pfizer

Sex: All·Age: 18+

Code: NCT04389632·Phase 1·Recruiting

Apply to this trial

Ph1b/2 Study of the Safety and Efficacy of T-DXd Combinations in Advanced HER2-expressing Gastric Cancer (DESTINY-Gastric03)

for Gastric Cancer

10 locations incl. Santa Monica

Sponsor: AstraZeneca

Sex: All·Age: 18 - 130

Code: NCT04379596·Phase 2·Recruiting

Apply to this trial

Testing the Addition of the Drug Apalutamide to the Usual Hormone Therapy and Radiation Therapy After Surgery for Prostate Cancer, INNOVATE Trial

for Prostate Adenocarcinoma

Drug: Apalutamide

345 locations incl. Phoenix

Sponsor: NRG Oncology

Sex: Male·Age: 18+

Code: NCT04134260·Phase 3·Recruiting

Apply to this trial

Expanded/Activated Gamma Delta T-cell Infusion Following Hematopoietic Stem Cell Transplantation and Post-transplant Cyclophosphamide

for Acute Myeloid Leukemia

2 locations incl. Westwood

Sponsor: University of Kansas Medical Center

Sex: All·Age: 18 - 65

Code: NCT03533816·Phase 1·Recruiting

Apply to this trial

Pan Tumor Rollover Study

for Cancer

59 locations incl. Huntsville

Sponsor: Bristol-Myers Squibb

Sex: All·Age: 18+

Code: NCT03899155·Phase 2·Recruiting

Apply to this trial

Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO

for Autoimmune Disease

Drug: Nivolumab

51 locations incl. Birmingham

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: 18+

Code: NCT03816345·Phase 1·Recruiting

Apply to this trial

Cabozantinib Plus Durvalumab With or Without Tremelimumab in Patients With Gastroesophageal Cancer and Other Gastrointestinal Malignancies

for Gastric Cancer

Drug: Cabozantinib

2 locations incl. Westwood

Sponsor: Anwaar Saeed

Sex: All·Age: 18+

Code: NCT03539822·Phase 1, Phase 2·Recruiting

Apply to this trial

Long-Term Follow-up Protocol for Participants Treated With Gene-Modified T Cells

for Neoplasms

100 locations incl. Birmingham

Sponsor: Celgene

Sex: All·Age: All ages

Code: NCT03435796·Phase 2, Phase 3·Recruiting

Apply to this trial

Conditions in Oncology (Westwood, KS)

Solid tumor· 11 Breast cancer· 10 Non-small cell lung cancer (NSCLC)· 10 Acute myeloid leukemia (AML)· 8 Multiple myeloma· 6 Non-Hodgkin lymphoma· 6 Colorectal cancer· 4 Chronic lymphocytic leukemia (CLL)· 4 Diffuse large B-cell lymphoma (DLBCL)· 4 Mantle cell lymphoma· 4 Hematologic malignancy· 4 Pancreatic cancer· 3 Gastric cancer· 3 Liver cancer· 3 Prostate cancer· 3 Metastatic prostate cancer· 3 Ovarian cancer· 3 Endometrial cancer· 3 Myelodysplastic syndromes (MDS)· 3 Myelofibrosis· 3 Follicular lymphoma· 3 Small lymphocytic lymphoma· 3 Melanoma· 3 Cancer (any)· 3 Metastatic breast cancer· 2 Triple-negative breast cancer· 2 Esophageal cancer· 2 Fallopian tube cancer· 2 Hodgkin lymphoma· 2 Head and neck cancer· 2 HER2-positive breast cancer· 1 HER2-negative breast cancer· 1 Gastroesophageal junction cancer· 1 Biliary tract cancer· 1 Gastrointestinal cancer· 1 Uterine cancer· 1 Acute lymphoblastic leukemia· 1 Marginal zone lymphoma· 1 Mesothelioma· 1